Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Annalisa Mondi
Observed names:
A Mondi,
A Mondì,
A. Mondi,
A. Mondì,
Mondi, Annalisa
Institution:
Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani
Observed institutions:
Università Cattolica del Sacro Cuore,
University of Rome Tor Vergata,
Università Campus Bio-Medico,
Agostino Gemelli University Polyclinic,
Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani,
Istituti di Ricovero e Cura a Carattere Scientifico
show all 6
ORCID:
0000-0003-4096-2610
Observed ORCID:
0000-0003-4096-2610
OpenAlex ID:
A5101946008
Monkeypox virus isolation from a semen sample collected in the early phase of infection in a patient with prolonged seminal viral shedding
2022
·
Daniele Lapa
, Fabrizio Carletti
, et al.
·
The Lancet Infectious Diseases
·
259
PDF
National Institute for the Infectious Diseases “L. Spallanzani” IRCCS. Recommendations for COVID-19 Clinical Management
2020
·
Emanuele Nicastri
, Nicola Petrosillo
, et al.
·
Infectious Disease Reports
·
204
Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against SARS-CoV-2 in People Living with HIV (PLWH) Receiving Antiretroviral Therapy (ART) According with Current CD4 T-Lymphocyte Count
2021
·
Andrea Antinori
, Stefania Cicalini
, et al.
·
Clinical Infectious Diseases
·
161
PDF
Immunological Signature in Human Cases of Monkeypox Infection in 2022 Outbreak
2022
·
Chiara Agrati
, Andrea Cossarizza
, et al.
·
The Lancet Infectious Diseases
·
113
PDF
Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study
2012
·
Mattia CF Prosperi
, Massimiliano Fabbiani
, et al.
·
BMC Infectious Diseases
·
112
PDF
Increase in Tuberculosis Diagnostic Delay during First Wave of the COVID-19 Pandemic: Data from an Italian Infectious Disease Referral Hospital
2021
·
Francesco Di Gennaro
, Gina Gualano
, et al.
·
Antibiotics
·
103
PDF
Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV
2022
·
Alessandra Vergori
, Alessandro Cozzi Lepri
, et al.
·
Nature Communications
·
101
PDF
Effectiveness of Dolutegravir-Based Regimens as Either First Line or Switch Antiretroviral Therapy: Data from the ICONA Cohort
2018
·
Annalisa Mondi
, Alessandro Cozzi‐Lepri
, et al.
·
Journal of the International AIDS Society
·
92
PDF
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M)
2016
·
Simona Di Giambenedetto
, Massimiliano Fabbiani
, et al.
·
Journal of Antimicrobial Chemotherapy
·
86
PDF
COVID‐19 in people living with HIV: Clinical implications of dynamics of the immune response to SARS‐CoV‐2
2020
·
Annalisa Mondi
, Eleonora Cimini
, et al.
·
Journal of Medical Virology
·
79
PDF
Contribution of Genetic Background, Traditional Risk Factors, and HIV-Related Factors to Coronary Artery Disease Events in HIV-Positive Persons
2013
·
Margalida Rotger
, Tracy R. Glass
, et al.
·
Clinical Infectious Diseases
·
79
PDF
Effect of local and remote ischemic preconditioning on endothelial function in young people and healthy or hypertensive elderly people
2011
·
L. Moro
, C. Pedone
, et al.
·
Atherosclerosis
·
65
Ocular involvement in monkeypox: Description of an unusual presentation during the current outbreak
2022
·
V Mazzotta
, A Mondi
, et al.
·
Journal of Infection
·
62
PDF
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study)
2013
·
S. Di Giambenedetto
, M. Fabbiani
, et al.
·
Journal of Antimicrobial Chemotherapy
·
57
Mpox as AIDS-defining event with a severe and protracted course: clinical, immunological, and virological implications
2023
·
Carmela Pinnetti
, Eleonora Cimini
, et al.
·
The Lancet Infectious Diseases
·
49
PDF
Immunogenicity and reactogenicity of modified vaccinia Ankara pre-exposure vaccination against mpox according to previous smallpox vaccine exposure and HIV infection: prospective cohort study
2024
·
Valentina Mazzotta
, Alessandro Cozzi Lepri
, et al.
·
EClinicalMedicine
·
44
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study
2015
·
A. Mondi
, M. Fabbiani
, et al.
·
Journal of Antimicrobial Chemotherapy
·
44
Risk of Chronic Kidney Disease among Patients Developing Mild Renal Impairment during Tenofovir-Containing Antiretroviral Treatment
2016
·
Giuseppe Lapadula
, Davide Paolo Bernasconi
, et al.
·
PLoS ONE
·
42
PDF
Declining Prevalence of Human Immunodeficiency Virus (HIV)–Associated Neurocognitive Disorders in Recent Years and Associated Factors in a Large Cohort of Antiretroviral Therapy–Treated Individuals With HIV
2022
·
Ilaria Mastrorosa
, Carmela Pinnetti
, et al.
·
Clinical Infectious Diseases
·
41
PDF
Kinetics of viral DNA in body fluids and antibody response in patients with acute Monkeypox virus infection
2023
·
Francesca Colavita
, Valentina Mazzotta
, et al.
·
iScience
·
38
Risk and predictive factors of prolonged viral RNA shedding in upper respiratory specimens in a large cohort of COVID-19 patients admitted to an Italian reference hospital
2021
·
Annalisa Mondi
, Patrizia Lorenzini
, et al.
·
International Journal of Infectious Diseases
·
38
PDF
Effect of tecovirimat on healing time and viral clearance by emulation of a target trial in patients hospitalized for mpox
2023
·
Valentina Mazzotta
, Alessandro Cozzi‐Lepri
, et al.
·
Journal of Medical Virology
·
37
Antiretroviral Neuropenetration Scores Better Correlate with Cognitive Performance of HIV-Infected Patients after Accounting for drug Susceptibility
2014
·
Massimiliano Fabbiani
, Pierfrancesco Grima
, et al.
·
Antiviral Therapy
·
37
PDF
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial
2018
·
Massimiliano Fabbiani
, Roberta Gagliardini
, et al.
·
Journal of Antimicrobial Chemotherapy
·
35
PDF
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study)
2013
·
Massimiliano Fabbiani
, Annalisa Mondi
, et al.
·
Scandinavian Journal of Infectious Diseases
·
31
Show more works
View as search
Works count:
116
Citation count:
2,814
H-index:
29
I10-index:
60
Year
Topic
Type